Envelope surface glycoprotein gp120
|
env
|
HIV-1 gp120 inhibits CD3-induced Lck activation and cellular tyrosine phosphorylation, particularly of phosphoinositide-specific phospholipase C-gamma-1 |
PubMed
|
|
env
|
Binding of HIV-1 gp120 to the CD4 receptor molecule results in co-stimulation of CD3-induced T cell activation |
PubMed
|
|
env
|
HIV-1 envelope glycoproteins gp120 and gp160 directly and specifically impair the CD3/TcR-mediated activation of phospholipase C (PLC) via the CD4 molecule in uninfected T cells |
PubMed
|
|
env
|
HIV-1 gp120 induces CD4 association with lymphocyte surface molecules CD3, CD11a, CD27, CD45RA, CD45RB, CD45RO, CD49d, CD38, CD26, CD59, CD95 and class I MHC molecules |
PubMed
|
|
env
|
Treatment of CD4+ T cells with HIV-1 gp120 significantly increases CD4 association with CD3, CD45RA, CD45RB, CD59, CD38, CD26 and HLA class I, and decreases that with CD45RC |
PubMed
|
Envelope surface glycoprotein gp160, precursor
|
env
|
HIV-1 gp160 interacts with CD3D; predicted interaction to be relevant to viral egress at plasma membrane/extracellular matrix |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
Gp41 TMD co-localizes with the CD3-TCR complex and inhibits T-cell activation induced by antibodies to CD3 |
PubMed
|
|
env
|
HIV-1 gp41 peptide (amino acids 581-597) inhibits lymphoproliferation stimulated via the T-cell-activation molecules CD3, CD2, and CD28, as well as via direct stimulation mediated by phorbol ester combined with ionomycin |
PubMed
|
Nef
|
nef
|
HIV-1 nef alleles from the great majority of primate lentiviruses, including HIV-2, downregulate TCR-CD3 from infected T cells and thereby block their responsiveness to activation |
PubMed
|
|
nef
|
HIV-1 Nef interacts with CD3 in living cells |
PubMed
|
Pr55(Gag)
|
gag
|
Monocyte-derived macrophages selectively capture and engulf HIV-1-infected CD4+ T cells as HIV-1 Gag interacts with CD3 and Caspase 3 markers, leading to efficient macrophage infection |
PubMed
|
|
gag
|
CD3/28-treated resting CD4+ T cells produce more HIV-1 Gag protein than untreated cells |
PubMed
|
|
gag
|
Interferon-gamma can counteract the inhibitory effect of peptides based on the Capsid protein of HIV-1 Gag on antibody response to SRC |
PubMed
|
|
gag
|
Peptides corresponding to amino acids 218-238 of the Capsid protein of HIV-1 Gag inhibited anti-CD3-induced lymphoproliferation but did not directly affect anti-CD2 activation |
PubMed
|
|
gag
|
Synthetic peptides corresponding to amino acids 218-238 of the Capsid protein of HIV-1 Gag have been shown to inhibit in a dose dependent manner the induction of a specific antibody response to the sheep red cell (SRC) antigen through the T3-Ti complex |
PubMed
|
Tat
|
tat
|
HIV-1 Tat interacts with CD3 and CD28 to co-stimulate IL-2 and IL-8 expression |
PubMed
|
Vpu
|
vpu
|
HIV-1 Vpu interacts with CD3 in living cells |
PubMed
|
capsid
|
gag
|
Synthetic peptides corresponding to amino acids 218-238 of HIV-1 Capsid have been shown to inhibit in a dose dependent manner the induction of a specific antibody response to the sheep red cell (SRC) antigen through the T3-Ti complex |
PubMed
|
|
gag
|
Interferon-gamma can counteract the inhibitory effect of HIV-1 Capsid based peptides on antibody response to SRC |
PubMed
|
|
gag
|
Peptides corresponding to amino acids 218-238 of HIV-1 Capsid inhibited anti-CD3-induced lymphoproliferation but did not directly affect anti-CD2 activation |
PubMed
|
matrix
|
gag
|
HIV-1 MA co-localizes with CD3 marker protein in monocyte-derived macrophages cocultured with HIV-1-infected primary CD4+ T-cells |
PubMed
|